Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Dreyling

Showing results (241-250 of 337) with videos related to

Pageof 34
Sort By:
Leukemia|July 7, 2026
Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histologyJonas Lippl, Sarah Reinke, Karoline Koch, et al.
Blood|January 29, 2021
LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcomeLorenz Thurner, Natalie Fadle, Jörg Thomas Bittenbring, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
Journal of Cancer Research and Clinical Oncology|August 30, 2024
Tumor board simulation improves interdisciplinary decision-making in medical studentsKevin Fink, Marie Forster, Matthias Oettle, et al.
Hemasphere|November 15, 2019
Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR StudyKlaus Herfarth, Peter Borchmann, Sven Schnaidt, et al.
Hemasphere|June 5, 2024
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAndreas J M Ferreri, Gerald Illerhaus, Jeanette K Doorduijn, et al.
American Journal of Hematology|August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCLKai Rejeski, Yucai Wang, Omar Albanyan, et al.
Leukemia & Lymphoma|May 31, 2017
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimusGeorg Hess, Simon Rule, Wojciech Jurczak, et al.
Leukemia & Lymphoma|August 20, 2011
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Hanneke C Kluin-Nelemans, Sílvia Beà, et al.
Haematologica|October 30, 2025
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020Linmiao Jiang, Marco Ladetto, Olivier Hermine, et al.
Pageof 34

Showing results (241-250 of 337) with videos related to

Sort By:
Pageof 34
Leukemia|July 7, 2026
Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histologyJonas Lippl, Sarah Reinke, Karoline Koch, et al.
Blood|January 29, 2021
LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcomeLorenz Thurner, Natalie Fadle, Jörg Thomas Bittenbring, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
Journal of Cancer Research and Clinical Oncology|August 30, 2024
Tumor board simulation improves interdisciplinary decision-making in medical studentsKevin Fink, Marie Forster, Matthias Oettle, et al.
Hemasphere|November 15, 2019
Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR StudyKlaus Herfarth, Peter Borchmann, Sven Schnaidt, et al.
Hemasphere|June 5, 2024
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAndreas J M Ferreri, Gerald Illerhaus, Jeanette K Doorduijn, et al.
American Journal of Hematology|August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCLKai Rejeski, Yucai Wang, Omar Albanyan, et al.
Leukemia & Lymphoma|May 31, 2017
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimusGeorg Hess, Simon Rule, Wojciech Jurczak, et al.
Leukemia & Lymphoma|August 20, 2011
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Hanneke C Kluin-Nelemans, Sílvia Beà, et al.
Haematologica|October 30, 2025
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020Linmiao Jiang, Marco Ladetto, Olivier Hermine, et al.
Pageof 34